Endocrine adjuvant therapy with the antiestrogen, mepitiostane, inoperable breast cancer patients on the basis of estrogen receptor assay.
D000731:Androstanes / Q000009:adverse effects / Q000627:therapeutic use*; D000732:Androstanols; D001943:Breast Neoplasms / Q000032:analysis / Q000188:drug therapy* / Q000601:surgery; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008599:Menstruation Disturbances / Q000139:chemically induced; D011960:Receptors, Estrogen / Q000032:analysis*; D013440:Sulfides / Q000009:adverse effects / Q000627:therapeutic use
D000731:Androstanes; D000732:Androstanols; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013440:Sulfides; C006242:mepitiostane